Cannasouth + Eqalis Merger

On 1 June 2023 Cannasouth merged with leading medicinal cannabis company Eqalis.

Together we will deliver better outcomes for patients – both locally and globally – by combining IP, technology, research and development, innovation, manufacturing, sales, and prescribing capabilities.

The Cannasouth Group now operates end-to-end with GMP approval for producing dried cannabis flower and manufacturing cannabis-based ingredients and medicinal cannabis products, including oral solutions.

This page contains all information available about the merger.

To view and download the Cannasouth and Eqalis proposed merger fact sheet please click here.


At the Special Shareholder Meeting of Cannasouth Limited (NZX:CBD) held in Auckland on 28 April 2023 at Link Market Services offices and online, shareholders overwhelmingly approved the proposed merger with Eqalis Group New Zealand Limited.

Below are links to documents relating to the Special Shareholder Meeting:

Results of Cannasouth Limited Special Shareholder Meeting

Notice of Meeting

Proxy Voting Form

Independent Adviser’s Report

Eqalis Audited Financial Statements 31 March 2022

Eqalis Unaudited Financial Statements 30 September 2022

To visit the Eqalis website, please click here.

To visit the RestoreMe website, please click here.